Our Pipeline
AUROBAC THERAPEUTICS’ R&D strategy encompasses patient- and pathogen-targeted programs designed to tackle both the causes and consequences of serious bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia, sepsis and septic shock. Central to this approach is the adoption of innovative diagnostic strategies developed in partnership with bioMérieux, aimed at facilitating patient stratification and optimizing treatment outcomes.
AUROBAC THERAPEUTICS aims to cover the entire value chain of projects, including research and development, clinical trials, registration, and commercialization.
ATX101New Chemical Entity
First-in-class therapeutic targeting the loss of vascular integrity in septic shock
Target indication: Treatment of early septic shock to prevent progression and improve outcome
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Discovery
- Preclinical
- Phase 1
- Phase 2
Partner
ATX401New Biological Entity
First engineered lysin active against multiple clinically-relevant Gram-negative pathogens
Target indication: Treatment of HAP/VAP caused by Gram-negative bacteria as 1st line therapy suppressing AMR emergence
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Discovery
- Preclinical
- Phase 1
- Phase 2
Partner
ATX2Hit Discovery Program
Internal Drug Discovery Engine to identify new Gram-negative antimicrobial peptides
Target indication: 2nd line precision treatment of infections caused by Gram-negative pathogens
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Discovery
- Preclinical
- Phase 1
- Phase 2
Partner
ATX3Hit Discovery Collaboration
Drug Discovery Engine to identify novel drug leads of microbial origin
Target indication: 2nd line precision treatment of infections caused by Gram-negative pathogens
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Discovery
- Preclinical
- Phase 1
- Phase 2
Partner
Partnership Ideas
If you have a breakthrough that you think will make an interesting collaboration, we would like to hear from you.
AUROBAC THERAPEUTICS is proud to be a member of the BEAM Alliance
AUROBAC ©2024 – Legal Notice – Privacy Statement – Photo Credits